celecoxib has been researched along with niacinamide in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G | 1 |
Li, Z; Wang, K; Zhang, H | 1 |
Booth, L; Carter, J; Dent, P; McGuire, WP; Poklepovic, A; Roberts, JL; Webb, T | 1 |
Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J | 1 |
Benech, N; Saurin, JC; Walter, T | 1 |
7 other study(ies) available for celecoxib and niacinamide
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Dinoprostone; Drug Synergism; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Sorafenib; Sulfonamides; Tumor Cells, Cultured | 2013 |
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; DNA Primers; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Microarray Analysis; Niacinamide; Phenylurea Compounds; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Sulfonamides | 2013 |
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Topics: Antineoplastic Agents; Carboplatin; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Inhibitory Concentration 50; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Phenylurea Compounds; Sildenafil Citrate; Sorafenib | 2015 |
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2016 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2017 |